



## RESEARCH NOTE

**REVISED** **Estimating the epidemiology of chronic Hepatitis B Virus (HBV) infection in the UK: what do we know and what are we missing? [version 2; peer review: 3 approved]**

Cori Campbell <sup>1,2</sup>, Tingyan Wang <sup>1,2</sup>, Rebekah Burrow<sup>3</sup>, Sema Mandal<sup>4,5</sup>, Julia Hippisley-Cox<sup>3</sup>, Eleanor Barnes <sup>2,6</sup>, Philippa C Matthews <sup>2,7-9</sup>

<sup>1</sup>Nuffield Department of Medicine, University of Oxford, Oxford, OX1 3XY, UK

<sup>2</sup>NIHR Oxford Biomedical Research Centre, Oxford, UK

<sup>3</sup>QResearch / Nuffield Dept of Primary Care, Oxford, UK

<sup>4</sup>National Institute for Health Research Health Protection Unit, London, UK

<sup>5</sup>Blood safety, Hepatitis, STI & HIV Division, UK Health Security Agency, London, UK

<sup>6</sup>Department of Hepatology, Oxford University Hospitals, John Radcliffe Hospital, Oxford, UK

<sup>7</sup>Department of Infectious Diseases, University College London Hospitals NHS Trust, London, UK

<sup>8</sup>The Francis Crick Institute, London, UK

<sup>9</sup>Division of Infection and Immunity, University College London, London, UK

**V2** First published: 08 Aug 2022, 7:203  
<https://doi.org/10.12688/wellcomeopenres.17941.1>

Latest published: 09 Mar 2023, 7:203  
<https://doi.org/10.12688/wellcomeopenres.17941.2>

**Abstract**

**Background:** HBV is the leading global cause of cirrhosis and primary liver cancer. However, the UK HBV population has not been well characterised, and estimates of UK HBV prevalence and/or incidence vary widely between sources. We aimed to i) extract and summarise existing national HBV prevalence estimates, ii) add a new estimate based on primary care data, and; iii) critique data sources from which estimates were derived.

**Methods:** We undertook a narrative review, searching for national estimates of CHB case numbers in the UK (incorporating incidence, prevalence and/or test positivity data) across a range of overlapping sources, including governmental body reports, publications from independent bodies (including medical charities and non-governmental organisations) and articles in peer-reviewed scientific journals. An alternative proxy for population prevalence was obtained via the UK antenatal screening programme which achieves over 95% coverage of pregnant women. We also searched for diagnoses of HBV in the QResearch primary care database based on laboratory tests and standardised coding.

**Results:** We identified six CHB case number estimates, of which three reported information concerning population subgroups, including number of infected individuals across age, sex and ethnicity categories. Estimates among sources reporting prevalence varied from 0.27% to 0.73%, congruent with an estimated antenatal CHB

**Open Peer Review**

Approval Status

	1	2	3
<b>version 2</b> (revision) 09 Mar 2023	 <a href="#">view</a>		 <a href="#">view</a>
<b>version 1</b> 08 Aug 2022	 <a href="#">view</a>	 <a href="#">view</a>	 <a href="#">view</a>

1. **Lung-Yi Mak** , The University of Hong Kong, Hong Kong, China

2. **Jonggi Choi** , University of Ulsan College of Medicine, Seoul, South Korea

3. **Anders Boyd**, HIV Monitoring Foundation, Amsterdam, The Netherlands

Any reports and responses or comments on the article can be found at the end of the article.

prevalence of <0.5%. Our estimate, based on QResearch data, suggests a population prevalence of ~0.05%, reflecting a substantial underestimation based on primary care records.

**Discussion:** Estimates varied by sources of error, bias and missingness, data linkage, and “blind spots” in HBV diagnoses testing/registration. The UK HBV burden is likely to be concentrated in vulnerable populations who may not be well represented in existing datasets including those experiencing socioeconomic deprivation and/or homelessness, ethnic minorities and people born in high-prevalence countries. This could lead to under- or over-estimation of population prevalence estimation. Multi-agency collaboration is required to fill evidence gaps.

### Keywords

hepatitis B virus, HBV, prevalence, epidemiology

**Corresponding author:** Philippa C Matthews ([philippa.matthews@crick.ac.uk](mailto:philippa.matthews@crick.ac.uk))

**Author roles:** **Campbell C:** Conceptualization, Data Curation, Formal Analysis, Investigation, Methodology, Visualization, Writing – Original Draft Preparation, Writing – Review & Editing; **Wang T:** Methodology, Supervision, Writing – Original Draft Preparation, Writing – Review & Editing; **Burrow R:** Writing – Review & Editing; **Mandal S:** Conceptualization, Investigation, Methodology, Writing – Original Draft Preparation, Writing – Review & Editing; **Hippisley-Cox J:** Methodology, Writing – Original Draft Preparation, Writing – Review & Editing; **Barnes E:** Conceptualization, Methodology, Supervision, Writing – Original Draft Preparation, Writing – Review & Editing; **Matthews PC:** Conceptualization, Formal Analysis, Investigation, Methodology, Supervision, Writing – Original Draft Preparation, Writing – Review & Editing

**Competing interests:** PCM is funded by Wellcome (grant ref 110110), by the Francis Crick Institute, and by University College London Hospitals NIHR BRC. CC’s doctoral project is funded by the Nuffield Department of Medicine, University of Oxford and by GlaxoSmithKline. EB is funded by the Oxford NIHR Biomedical Research Centre and is an NIHR Senior Investigator. The views expressed in this article are those of the author and not necessarily those of the NHS, the NIHR, or the Department of Health. PCM, EB and CC are supported by the DeLIVER program “The Early Detection of Hepatocellular Liver Cancer” project is funded by Cancer Research UK (Early Detection Programme Award, grant reference: C30358/A29725). EB, TW, CC and PCM acknowledge support from the NIHR Health Informatics Collaborative. JH-C is an unpaid director of QResearch, a not-for-profit organisation which is a partnership between the University of Oxford and EMIS Health that supplies the QResearch Database used for this work. JH-C is chair of the NERVTAG subgroup on risk stratification and a member of SAGE groups on data and ethnicity. JH-C is a founder and shareholder of ClinRisk and was its medical director until 31 May 2019.

**Grant information:** PCM is funded by Wellcome (grant ref 110110), by the Francis Crick Institute, and by University College London Hospitals NIHR BRC. CC’s doctoral project is funded by the Nuffield Department of Medicine, University of Oxford and by GlaxoSmithKline. EB is funded by the Oxford NIHR Biomedical Research Centre and is an NIHR Senior Investigator. The views expressed in this article are those of the author and not necessarily those of the NHS, the NIHR, or the Department of Health. PCM, EB and CC are supported by the DeLIVER program “The Early Detection of Hepatocellular Liver Cancer” project is funded by Cancer Research UK (Early Detection Programme Award, grant reference: C30358/A29725). EB, TW, CC and PCM acknowledge support from the NIHR Health Informatics Collaborative. JH-C is an unpaid director of QResearch, a not-for-profit organisation which is a partnership between the University of Oxford and EMIS Health that supplies the QResearch Database used for this work. JH-C is chair of the NERVTAG subgroup on risk stratification and a member of SAGE groups on data and ethnicity. JH-C is a founder and shareholder of ClinRisk and was its medical director until 31 May 2019.

*The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.*

**Copyright:** © 2023 Campbell C *et al.* This is an open access article distributed under the terms of the [Creative Commons Attribution License](https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

**How to cite this article:** Campbell C, Wang T, Burrow R *et al.* **Estimating the epidemiology of chronic Hepatitis B Virus (HBV) infection in the UK: what do we know and what are we missing? [version 2; peer review: 3 approved]** Wellcome Open Research 2023, 7:203 <https://doi.org/10.12688/wellcomeopenres.17941.2>

**First published:** 08 Aug 2022, 7:203 <https://doi.org/10.12688/wellcomeopenres.17941.1>

**REVISED Amendments from Version 1**

We have modified our manuscript to emphasise that we undertook a narrative literature review to summarise population-wide chronic HBV infection prevalence estimates produced to date. We have also considered additional data sources suggested by reviewers, and updated our discussion accordingly to reflect this

**Any further responses from the reviewers can be found at the end of the article**

**Introduction**

Hepatitis B virus (HBV) is the leading global cause of cirrhosis, and of primary liver cancer incidence and mortality<sup>1,2</sup>. Nearly 300 million individuals worldwide are estimated to be living with chronic HBV (CHB) infection. Risks of complications and death are mitigated by screening to detect cases of infection, clinical monitoring of chronic infection (including liver cancer surveillance in high-risk cases), and antiviral therapy in those who meet treatment criteria<sup>3</sup>.

The United Kingdom (UK) is regarded as a low prevalence setting for CHB<sup>3,4</sup>. However, the attributable disease burden may be substantial in specific population subgroups including people who inject drugs, the prison population, people experiencing homelessness, and individuals belonging to minority ethnic groups and born in countries where the prevalence of CHB is higher<sup>5</sup>. Thus, CHB is concentrated in potentially under-served, vulnerable and/or disadvantaged population subgroups<sup>6</sup>.

Epidemiological characterisation of the UK CHB population has been limited, with no central registry of infected persons. Existing data may primarily reflect new diagnoses (a combination of incident acute infection and new diagnoses of chronic infection), but caution is needed in making inferences about prevalence. Accurate estimation of prevalence is challenging, because complete HBV data are not likely to be well captured by large-scale electronic health record (EHR) databases for either primary or secondary care<sup>7</sup>, as many CHB cases remain untested and therefore undiagnosed. Addressing the lack of HBV summary data in the UK would aid researchers and policy makers in addressing further evidence gaps.

The World Health Organization (WHO) has set targets for viral hepatitis elimination within its Sustainable Development Goals for 2030. The Global Health Sector Strategy on Viral Hepatitis<sup>8</sup> identifies specific goals, including diagnosis in 90% of chronic infections, 90% reduction in incidence of chronic infection, and 80% treatment coverage in those eligible. High quality epidemiological data are therefore crucial to focus and measure progress, inform policy and interventions, reduce inequities and underpin resource allocation. We therefore aimed to i) extract and summarise existing national HBV prevalence estimates; (ii) present new data from the QResearch primary care database; and (iii) summarise and critique the data sources from which these estimates were derived.

**Methods**

We searched for estimates of CHB case numbers in the UK (incorporating incidence and/or prevalence-like data) across a range of available sources in a narrative (rather than systematic) review approach. We included UK-wide reports from government bodies, publications from independent bodies (including medical charities and non-governmental organisations) and articles in peer-reviewed scientific journals, excluding smaller epidemiological studies when there was overlap of data sources with larger samples from other studies. We present positivity rates from each respective data source, but caution that these estimates are not representative of the true UK-wide population prevalence. Details of study samples/denominator are provided. The Office for National Statistics (ONS) provides UK population estimates as a point of reference for the overall denominator<sup>9</sup>.

We also generated a new prevalence estimate, utilising data from the UK primary care database QResearch, which contains over 35 million patient records from more than 1800 individual practices<sup>10</sup>. QResearch was established in 2002 and contains anonymised individual-level patient EHR. Data are collected prospectively and are linked to hospital episode statistics (HES), National Cancer Registration Analysis Service (NCRAS) and ONS mortality data. QResearch ethics approval is with East Midlands-Derby Research Ethics Committee (reference 18/EM/0400).

We identified individuals in the QResearch (version 44) database who had a record of a diagnostic Systemised Nomenclature of Medicine (SNOMED)/Read or International Classification of Disease (ICD) code indicative of CHB, or who had a history of  $\geq 1$  hepatitis B surface antigen (HBsAg) or viral load (VL) measurement. From this sample we identified individuals between 01 January 1999 and 31 December 2019, age  $\geq 18$  years with CHB, defined as: i) record of a diagnostic SNOMED/Read code indicating CHB; or ii) record of a diagnostic ICD-9 or -10 code indicating CHB; and/or iii) Presence of HBsAg or VL on  $\geq 2$  recordings  $\geq 6$  months apart. The characteristics of HBV infection in the cases we identified are further described elsewhere<sup>9</sup>.

We have also drawn on findings from a similar investigation previously undertaken in the Clinical Practice Research Datalink (CPRD)<sup>11</sup>, which is another UK primary care database containing EHRs for over 16 million patients. This previous investigation identified CHB individuals from patients registered in the database between 2000 and 2015.

This article can be found on medRxiv<sup>12</sup>.

**Results and discussion**

UK data for CHB epidemiology are summarised in [Table 1](#). Three of six estimates report information concerning population demographics, including number of infected individuals across age, sex and ethnicity categories. Among sources setting out to report prevalence, estimates varied from 0.27% (British

**Table 1. Prevalence estimates for chronic hepatitis B virus (HBV) infection in sub-populations in the United Kingdom.**

Estimate source	Population and/or data source (study period/year)	Sources and citation(s)	Estimate type	Denominator (population tested)	Number of adults testing positive for HBV infection	Percentage infected with HBV in study/survey population (%)	Information on relevant population characteristics†
<b>PHE / UKHSA</b>	Individuals tested for HBsAg in 19 participating laboratories (excludes testing in antenatal services and reference lab testing; deduplicated using identifiers where available) (2020)	Sentinel surveillance of BBV testing <sup>13</sup>	Positivity amongst those tested (diagnosed prevalence)	302,135	2611	0.86%	Yes: information by ethnicity, sex, age, region
<b>Polaris Observatory<sup>14</sup></b>	Modelling study based on literature review and expert interviews (2016)	Razavi-Shearer <i>et al.</i> , 2018 <sup>14</sup>	UK HBV population prevalence	2016 UK population of 65,648,000 <sup>15</sup>	440,000	0.73%	No
<b>PHE Infectious Diseases in Pregnancy Screening Programme</b>	Pregnant women attending antenatal services in England (April 2019-March 2020)	Antenatal screening standards data report 1 April 2019 – 31 March 2020 <sup>16</sup>	Antenatal population prevalence	Pregnant women attending antenatal services 661,281 (screening coverage of 99.8%)	2493	0.38%	No
<b>BLT<sup>17*</sup></b>	Source unavailable (likely 2002) <sup>§</sup>	NICE guidelines <sup>18,19**</sup>	Number of people in the UK positive for HBV - prevalence	Not clearly stated – likely 2002 UK population of 59,365,677 <sup>20</sup>	180,000	0.27%	No
<b>CPRD</b>	CPRD primary care database consisting of EHRs from >16 million patients (2000 to 2015)	Ferreira <i>et al.</i> <sup>10</sup>	Number of CHB diagnoses in database	CPRD subset of EHRs from 4.4 million patients <sup>¶</sup>	3927	0.09%	Yes
<b>QResearch cohort<sup>21</sup></b>	QResearch primary care database (1999 to 2019)	CCCC-UK cohort <sup>9</sup>	Number of CHB diagnoses in database	QResearch database subset of EHRs from 16.9 million patients <sup>7</sup>	8039	0.05%	Yes

HBV, Hepatitis B virus; UKHSA, United Kingdom Health Security Agency; PHE, Public Health England; PWID, people who inject drugs; BLT, British Liver Trust; NICE, National Institute for Health and Care Excellence; CPRD, Clinical Practice Research Datalink; CHB chronic Hepatitis B virus infection; EHR, electronic health record; CCCC, Characteristics of Chronic Hepatitis B associated with Cirrhosis and Cancer.

\* The British Liver Trust published a HBV report in 2017 stating that approximately 180,000 people live with chronic HBV infection in the UK<sup>7</sup>. This report cited a governmental migrant health guide citing this prevalence estimate<sup>18</sup>. The source which this government report cited was a National Institute for Health and Care Excellence (NICE) testing guideline which stated this prevalence estimate and dated it to 2002<sup>19</sup>.

† May include but is not limited to: age, sex, ethnicity and socioeconomic status.

‡ Sources include "laboratory data and sentinel surveillance data"<sup>13</sup>.

§ Department of Health 2002 report cited<sup>20</sup> is unavailable for download. No clear methodology reported

¶ Subset of total (16.9 million) patients in CPRD with valid EHR information and temporality who were acceptable for research<sup>10</sup>.

Liver Trust / Department of Health and Social Care (DHSC 2002 estimate) to 0.73% (estimate by the Polaris Institute). An alternative proxy for population prevalence is obtained via the UK antenatal screening programme, which achieves over 95% coverage of every pregnant woman annually (approx. 700,000 women in the UK), with a CHB prevalence of <0.5%<sup>13</sup>. Differences between sources highlights varied sources of error, bias and missingness, problems with data linkage, and substantial “blind spots” in consistent testing and registration of HBV diagnoses.

As HBV is a notifiable disease in the UK, the UK Health Security Agency, UKHSA (previously Public Health England, PHE), has a comprehensive surveillance system for monitoring burden of CHB, by monitoring testing and diagnoses across the care pathway. This incorporates data from diagnoses through to outcomes, (including end-stage liver disease, transplantation, liver cancer and deaths) using laboratory testing surveillance (sentinel surveillance of blood-borne virus (BBV) testing in primary and secondary care settings), new laboratory diagnoses, hospital activity datasets and registries (NHS Digital hospital episode statistics, ONS cancer and deaths registries, NHS Blood and Transplant registry). However, these data have not yet been combined and incorporated in a statistical model to estimate prevalence. Sentinel surveillance captures testing in community, primary care and secondary care settings across a network of laboratories covering approximately 40% of the general population of England<sup>13</sup>. This likely gives the best estimate of diagnosed prevalence among a tested population, but because it combines acute incident infections and new diagnoses of pre-existing chronic infection, incidence and prevalence cannot be disaggregated.

The majority of diagnostic data are generated through testing individuals with risk factors for HBV infection or evidence of liver disease, and among those accepting risk-based testing (as captured in laboratory testing surveillance) likely overestimates the overall population prevalence. Alternative estimates can be generated from screening blood donors<sup>22</sup>, but this group are self-selected low-risk individuals who have undergone deferral discussions<sup>23–25</sup>, and are predominantly UK born, and therefore are not representative of the general population, leading to an under-estimate of prevalence<sup>23</sup>. No existing estimates factor in the undiagnosed burden, which represents the majority of people living with HBV infection (the WHO estimates that only 10.5% of people with CHB are aware of their infection status<sup>3</sup>). Furthermore, the highest prevalence of CHB is in groups for whom provision of healthcare is inadequate, and/or access to healthcare is challenging (including migrants, sex-workers, prisoners, and people experiencing homelessness), so overall there are still many gaps in the data, and it is most likely that estimates using primary care datasets considerably underestimate the true burden<sup>6</sup>. There is a need for more evidence to delineate epidemiology in these populations.

Previous investigation has reported an increased burden of HBV infection in young, male, socioeconomically deprived individuals belonging to ethnic minorities within the UK<sup>26</sup>. These individuals comprise a larger percentage of the London city population as compared to other regions in the UK, and therefore regional differences must be considered when deriving a population-wide prevalence estimate, which can be achieved through statistical models.

Less biased estimates are achieved by non-targeted testing programmes such as universal antenatal screening. Opt-out screening of blood drawn from patients admitted to a selection of Emergency Departments (EDs) for HBV, HCV and HIV is being piloted across 34 sites across the UK, with new HBV diagnoses outnumbering HIV or HCV by >2:1 in the first 100 days<sup>27</sup>. Over time, expansion of this programme should provide an additional valuable source of epidemiological data.

While UKHSA surveillance data may include some demographic characteristics (age, sex, postcode for deprivation), unless linked to other healthcare datasets, they typically lack more detailed clinical and demographic indicators (for example, measures of deprivation, lifestyle factors, assessment of liver disease, and HBV treatment coverage) which are needed to characterise the infected population. In contrast, EHR databases (such as CPRD and QResearch) have the advantage of collecting relevant demographic and clinical metadata which are not captured by UKHSA. However, linkage across data sources is disaggregated, and thereby each EHR-based estimate misses a portion of the infected population. For example, primary care data may not reflect testing conducted in secondary care<sup>28</sup>, blood safety (transfusion/transplantation) and laboratory data generated by other services, while secondary care data are typically only reliable for the sub-population enrolled in consistent hospital follow-up. Poor data flow between diagnostic testing and EHR reflect a low clinical follow-up rate following a positive HBsAg test. This limited linkage to care reflects how services may not provide well for the CHB population, with gaps in referral pathways, inadequate communication and education (including translation services), and failures to deliver services to marginalised communities. Therefore, EHR databases offer the potential to characterise a subset of those infected with HBV, but do not currently generate a picture that is generalisable to the wider infected population, and cannot on their own be used to estimate prevalence.

Prevalence estimates for Hepatitis C virus (HCV)<sup>29</sup> and human immunodeficiency virus (HIV)<sup>30</sup> have recently been generated using multi-parameter evidence synthesis and back-calculation models. Similar modelling approaches to produce estimates of HBV incidence and prevalence in the UK are warranted. Enhanced investment is needed to support the establishment of national registries with robust centralised data linkage between sources including national laboratory surveillance systems of BBV testing and new diagnoses, and thus determine which

**Summary box: Recommendations for the generation of enhanced insights into national CHB epidemiology and caseload, and evidence gaps to be addressed with each recommendation**

Recommendation	Evidence gap addressed
Expansion of systematic screening, including opportunistic approaches (sexual health, antenatal, emergency medicine, people born in high-prevalence settings) to better understand HBV epidemiology in the UK.	Lack of knowledge of UK HBV epidemiology and distribution.
Improved centralised data linkage between services, including laboratory records, blood and transplant services, primary and secondary care, supported by collection of metadata.	Inefficient use of administrative health data for research and to inform policy and service delivery.
Disaggregation of incidence/prevalence data where possible at source.	Lack of clarity regarding existing and incident burden of HBV.
Establishment of regional and/or national registries to collate linked data for HBV infection at a population level and within high risk groups.	Lack of comprehensive identification of infections at a regional/national level, and poor representation of high risk groups.
Mathematical modelling to optimise use of existing data to generate incidence, prevalence and caseload estimates (accounting for variations between geographic centers and populations)	Lack of a robust national-level prevalence estimate, and refinement to identify differences between population groups.
Efficient use of existing data sources to identify systematic data gaps, refine allocation of resources and predict progress towards elimination targets.	Insufficient progress towards elimination targets required to achieve elimination of viral hepatitis as a public health threat by 2030.

population subgroups are bearing the majority of the HBV disease burden. This will inform prevalence modelling and provide an evidence base for delivery of appropriate resources and interventions, and to benchmark progress towards elimination targets.

### Ethics approval

QResearch ethics approval is with East Midlands-Derby Research Ethics Committee (reference 18/EM/0400).

### Data availability

Only CC, TW, RB and JH-C have access to the QResearch individual-level patient data in order to ensure confidentiality of personal and health information, in accordance with the relevant licence agreements. QResearch data access is according to the information on the QResearch website ([www.qresearch.org](http://www.qresearch.org)).

### Author contributions

PM and CC conceptualised the study. CC conducted the literature search for estimates, and drafted the manuscript with PM. JH-C, RB, SM, TW and EB provided methodological input. JH-C, SM, TW and EB revised the manuscript.

### Acknowledgements

Access to the data was facilitated by the PHE Office for Data Release. We acknowledge the contribution of EMIS practices who contribute to QResearch® and EMIS Health and the CHANCELLOR MASTERS AND SCHOLARS OF THE UNIVERSITY OF OXFORD for expertise in establishing, developing and supporting the QResearch database. United Kingdom Health Security Agency bear no responsibility for the analysis or interpretation of the data. We would like to thank Iain Gillespie at GSK for his helpful comments on the manuscript.

### References

- Global Burden of Disease Liver Cancer Collaboration, Akinyemiju T, Abera S, et al.: **The burden of primary liver cancer and underlying etiologies from 1990 to 2015 at the global, regional, and national level: results from the global burden of disease study 2015.** *JAMA Oncol.* 2017; 3(12): 1683–91. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
- GBD 2017 Cirrhosis Collaborators: **The global, regional, and national burden of cirrhosis by cause in 195 countries and territories, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017.** *Lancet Gastroenterol Hepatol.* 2020; 5(3): 245–66. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
- WHO: **Hepatitis B Fact Sheet.** 2021. [Reference Source](#)

4. GBD 2019 Hepatitis B Collaborators: **Global, regional, and national burden of hepatitis B 1990-2019: a systematic analysis for the Global Burden of Disease Study 2019**. *Lancet Gastroenterol Hepatol*. 2022; 7(9): 796–829. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
5. **Hepatitis B in London: 2016 data**. 2019; [cited 2020 Oct 2]. [Reference Source](#)
6. Martyn E, Eisen S, Longley N, *et al.*: **The forgotten people: Hepatitis B virus (HBV) infection as a priority for the inclusion health agenda**. *Elife*. 2023; 12: e81070. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
7. **Data**. QResearch, [cited 2022 Feb 6]. [Reference Source](#)
8. **Global Health Sector Strategy on viral hepatitis 2016-2021**. Geneva; 2016; [cited 2021 Jun 14]. [Reference Source](#)
9. Campbell C, Wang T, Barnes E, *et al.*: **Baseline characteristics of a large multi-site chronic HBV electronic health record-based cohort in the UK**. *F1000Res*. 2021; 10. [Publisher Full Text](#)
10. Ferreira G, Stuurman AL, Horsmans Y, *et al.*: **Hepatitis B virus infection and the risk of liver disease progression in type 2 diabetic patients with potential nonalcoholic fatty liver disease: a retrospective, observational, cohort study in the United Kingdom Clinical Practice Research Datalink**. *Eur J Gastroenterol Hepatol*. 2020; 32(1): 101–9. [PubMed Abstract](#) | [Publisher Full Text](#)
11. Mandal S, Hayden I, Neal J, *et al.*: **Demonstrating control of perinatal transmission of hepatitis B in the UK: a low prevalence country with universal antenatal screening and selective neonatal immunisation programmes**. EASL Viral Hepatitis Elimination Conference 24-25 Poster Abstract PO 75. 2022; [cited 2022 Mar 29]. [Reference Source](#)
12. Campbell C, Wang T, Burrow R, *et al.*: **Estimating the epidemiology of chronic Hepatitis B Virus (HBV) infection in the UK: what do we know and what are we missing?** *medRxiv*. 2022; 2022.04.12.22273568. [Publisher Full Text](#)
13. Public Health England: **Annual report from the sentinel surveillance of blood borne virus testing in England 2020: main report**. 2021; 15(13). [Reference Source](#)
14. Polaris Observatory Collaborators: **Global prevalence, treatment, and prevention of hepatitis B virus infection in 2016: a modelling study**. *Lancet Gastroenterol Hepatol*. 2018; 3(6): 383–403. [PubMed Abstract](#) | [Publisher Full Text](#)
15. Office for National Statistics: **Population estimates for the UK, England and Wales, Scotland and Northern Ireland: mid-2016**. 2017; [cited 2022 Mar 29]. [Reference Source](#)
16. Public Health England: **Antenatal screening standards: data report 1 April 2019 to 31 March 2020**. GOV.UK, 2021; [cited 2022 Mar 29]. [Reference Source](#)
17. British Liver Trust: **Hepatitis B**. 2017. [Reference Source](#)
18. Public Health England: **Hepatitis B: migrant health guide**. GOV.UK, 2017 [cited 2022 Feb 8]. [Reference Source](#)
19. **Hepatitis B and C testing: people at risk of infection (PH43)**. 2012 [cited 2022 Feb 8]. [Reference Source](#)
20. **[ARCHIVED CONTENT] Getting ahead of the curve: a strategy for combating infectious diseases (including other aspects of health protection)**. Department of Health - Publications, [cited 2022 Feb 15]. [Reference Source](#)
21. **Characteristics of Chronic Hepatitis B associated with Cirrhosis and Cancer**. [cited 2020 Aug 18]. [Reference Source](#)
22. Harvala H, Reynolds C, Gibney Z, *et al.*: **Hepatitis B infections among blood donors in England between 2009 and 2018: Is an occult hepatitis B infection a risk for blood safety?** *Transfusion*. 2021 [cited 2023 Feb 23]; 61(8): 2402–2413. [PubMed Abstract](#) | [Publisher Full Text](#)
23. Joint United Kingdom (UK) Blood Transfusion and Tissue Transplantation Services Professional Advisory Committee: **Guidelines for the Blood Transfusion Services in the UK**. 2013 [cited 2023 Feb 20]. [Reference Source](#)
24. **Data sources and methods 2020: NHS Blood and Transplant and UK Health Security Agency**. NHS Blood and Transplant. 2021 [cited 2023 Feb 20]. [Reference Source](#)
25. Reynolds C, Davison KL, Brailsford SR: **Safe supplies: few infections in UK blood and tissue donors**. *Transfus Med*. 2019 [cited 2023 Feb 20]; 29(4): 239–46. [PubMed Abstract](#) | [Publisher Full Text](#)
26. Campbell C, Wang T, Gillespie I, *et al.*: **Characterisation of chronic hepatitis B virus infection in the UK and risk factors for hepatocellular carcinoma: a large electronic health record-based retrospective cohort study in the QResearch primary care database**. *medRxiv*. 2022 [cited 2022 Sep 7]; 2022.09.01.22279481. [Publisher Full Text](#)
27. **NHS England » Emergency department opt out testing for HIV hepatitis B and hepatitis C: The first 100 days**. [cited 2023 Jan 16]. [Reference Source](#)
28. Wang T, Smith DA, Campbell C, *et al.*: **Cohort Profile: National Institute for Health Research Health Informatics Collaborative: Hepatitis B Virus (NIHR HIC HBV) Research Dataset**. *medRxiv*. 2021; 2021.10.21.21265205. [Publisher Full Text](#)
29. Harris RJ, Harris HE, Mandal S, *et al.*: **Monitoring the hepatitis C epidemic in England and evaluating intervention scale-up using routinely collected data**. *J Viral Hepat*. 2019; 26(5): 541–551. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
30. Presanis AM, Harris RJ, Kirwan PD, *et al.*: **Trends in undiagnosed HIV prevalence in England and implications for eliminating HIV transmission by 2030: an evidence synthesis model**. *Lancet Public Health*. 2021; 6(10): e739–51. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)

# Open Peer Review

Current Peer Review Status:   

---

## Version 2

Reviewer Report 15 March 2023

<https://doi.org/10.21956/wellcomeopenres.21210.r55464>

© 2023 **Boyd A.** This is an open access peer review report distributed under the terms of the [Creative Commons Attribution License](#), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.



**Anders Boyd**

HIV Monitoring Foundation, Amsterdam, The Netherlands

All concerns were addressed.

**Competing Interests:** No competing interests were disclosed.

**Reviewer Expertise:** HBV, HIV, STI, epidemiology, biostatistics

**I confirm that I have read this submission and believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard.**

Reviewer Report 10 March 2023

<https://doi.org/10.21956/wellcomeopenres.21210.r55465>

© 2023 **Mak L.** This is an open access peer review report distributed under the terms of the [Creative Commons Attribution License](#), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.



**Lung-Yi Mak** 

Department of Medicine, Queen Mary Hospital, The University of Hong Kong, Hong Kong, China

The authors have addressed the salient comments.

**Competing Interests:** No competing interests were disclosed.

**Reviewer Expertise:** chronic hepatitis B infection, clinical liver disease

**I confirm that I have read this submission and believe that I have an appropriate level of**



expertise to confirm that it is of an acceptable scientific standard.

---

## Version 1

Reviewer Report 11 January 2023

<https://doi.org/10.21956/wellcomeopenres.19882.r53572>

© 2023 Boyd A. This is an open access peer review report distributed under the terms of the [Creative Commons Attribution License](#), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.



### Anders Boyd

<sup>1</sup> HIV Monitoring Foundation, Amsterdam, The Netherlands

<sup>2</sup> HIV Monitoring Foundation, Amsterdam, The Netherlands

In their manuscript, Campbell et al describe the available sources used to estimate the case numbers of hepatitis B virus (HBV) in the United Kingdom, while highlighting the major gaps in understanding HBV epidemiology in the country. The details on the data sources retrieved are clear, along with their limitations. I found the discussion to be particularly helpful. Nevertheless, there are some issues worth addressing.

I appreciate that this is a narrative review, yet the information on what was searched (i.e., which keywords), in which locations (i.e., with which search engines/sources) and when (i.e., years in which databases were allowed) is unclear. It would also be helpful to include some notion of which databases were included and excluded. For instance, it seems that many small epidemiological studies intended to find prevalence or incidence in very specific demographic populations could be missed (which could help address some of the gaps stated by the authors). Including this information would help guide the reader as to how the authors arrived at their selection.

I also very much appreciate the summary box, which includes recommendations on how to achieve national CHB caseloads. But given the low prevalence of HBV and higher prevalence in specific key populations, would it make sense to aim for a national CHB caseload estimate? The aim of these recommendations should more reflect what the authors stated in their title, towards understanding the epidemiology of HBV in the United Kingdom. It would also be helpful to include a column in this box with the gap(s) in knowledge corresponding to the given recommendation, so the reader can identify the limitations of existing data (and hopefully avoid it in the future).

Finally, it is unclear why prevalence estimates were given in the results, or even why this was examined in the first place if the aim was to discuss data sources to understand HBV epidemiology (i.e., data sources that have an estimate of HBV prevalence). I would suggest that the authors make it clear why this statistic was included, possibly by adding it as a secondary objective.

Minor comments:

- Abstract. "...(incorporating incidence and/or prevalence like data)..." is ambiguous. Please clarify.
- Abstract. "sources of error" refers to what exactly? This term could be deleted as it seems that bias was more the focal point of the discussion.
- Abstract. Although I agree with the sentence, "Multi-parameter evidence ... may be applicable to HBV." – this does not really seem appropriate for the abstract (as the result backing this argument is missing in the Abstract).
- Introduction. The information on ERH is probably more appropriate for the discussion. The third paragraph in the introduction should focus not only on the limited data, but also the lack of summary on HBV data in the UK. This information could be used to help policy makers understand what exactly are the gaps in knowledge.
- Introduction. It should be stated clearly in the aims that this is a narrative review (for readers who may confuse this with a systematic review and meta-analysis).

**Is the work clearly and accurately presented and does it cite the current literature?**

Yes

**Is the study design appropriate and is the work technically sound?**

Partly

**Are sufficient details of methods and analysis provided to allow replication by others?**

Partly

**If applicable, is the statistical analysis and its interpretation appropriate?**

Not applicable

**Are all the source data underlying the results available to ensure full reproducibility?**

No source data required

**Are the conclusions drawn adequately supported by the results?**

Yes

**Competing Interests:** No competing interests were disclosed.

**Reviewer Expertise:** HBV, HIV, STI, epidemiology, biostatistics

**I confirm that I have read this submission and believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard, however I have significant reservations, as outlined above.**

Author Response 24 Feb 2023

**Cori Campbell**

We are grateful to reviewers for their helpful comments. We have provided a point-by-point rebuttal below, and highlighted changes in the manuscript in tracked changes. In their manuscript, Campbell et al describe the available sources used to estimate the case numbers of hepatitis B virus (HBV) in the United Kingdom, while highlighting the major gaps in understanding HBV epidemiology in the country. The details on the data sources retrieved are clear, along with their limitations. I found the discussion to be particularly helpful. Nevertheless, there are some issues worth addressing.

I appreciate that this is a narrative review, yet the information on what was searched (i.e., which keywords), in which locations (i.e., with which search engines/sources) and when (i.e., years in which databases were allowed) is unclear. It would also be helpful to include some notion of which databases were included and excluded. For instance, it seems that many small epidemiological studies intended to find prevalence or incidence in very specific demographic populations could be missed (which could help address some of the gaps stated by the authors). Including this information would help guide the reader as to how the authors arrived at their selection.

**Response: many thanks for your review and very helpful comments. We undertook a narrative rather than systematic review and as such did not search through databases. We excluded small epidemiological studies in order to both avoid duplication of sources, and because our aim was to summarise the range of national prevalence estimates that have been produced to date. We have modified the first two sentences of the Methods section to clarify this: We searched for estimates of CHB case numbers in the UK (incorporating incidence and/or prevalence data) across a range of available sources in a narrative (rather than systematic) review approach. We included UK-wide reports from government bodies, publications from independent bodies (including medical charities and non-governmental organisations) and articles in peer-reviewed scientific journals, excluding smaller epidemiological studies when there was overlap of data sources with larger samples from other studies. Please note that in addition to the review approach, we have also included new data from the QResearch (primary care) database, which we have now highlighted more specifically in the abstract and methods section.**

I also very much appreciate the summary box, which includes recommendations on how to achieve national CHB caseloads. But given the low prevalence of HBV and higher prevalence in specific key populations, would it make sense to aim for a national CHB caseload estimate? The aim of these recommendations should more reflect what the authors stated in their title, towards understanding the epidemiology of HBV in the United Kingdom. It would also be helpful to include a column in this box with the gap(s) in knowledge corresponding to the given recommendation, so the reader can identify the limitations of existing data (and hopefully avoid it in the future). **Many thanks for your suggestions, we have modified the title of the Summary Box and the information presented to incorporate these recommendations.**

Finally, it is unclear why prevalence estimates were given in the results, or even why this was examined in the first place if the aim was to discuss data sources to understand HBV epidemiology (i.e., data sources that have an estimate of HBV prevalence). I would suggest

that the authors make it clear why this statistic was included, possibly by adding it as a secondary objective. **Our aim was to summarise national HBV prevalence estimates produced to date, and discuss data sources from which these estimates were derived. We have modified the final sentence of the Introduction section to explicitly state our aims: We therefore aimed to i) extract and summarise existing national HBV prevalence estimates; (ii) present new data from the QResearch primary care database; and iii) summarise and critique the data sources from which these estimates were derived.**

Minor comments:

- Abstract. "...(incorporating incidence and/or prevalence like data)..." is ambiguous. Please clarify. **Thank you, we've now removed "like" to clarify.**

- Abstract. "sources of error" refers to what exactly? This term could be deleted as it seems that bias was more the focal point of the discussion. **Thank you, we've now deleted this to clarify.**

- Abstract. Although I agree with the sentence, "Multi-parameter evidence ... may be applicable to HBV." – this does not really seem appropriate for the abstract (as the result backing this argument is missing in the Abstract). **Thank you, we've now modified this to be appropriate.**

- Introduction. The information on ERH is probably more appropriate for the discussion. The third paragraph in the introduction should focus not only on the limited data, but also the lack of summary on HBV data in the UK. This information could be used to help policy makers understand what exactly are the gaps in knowledge. **Thank you for your comment. We have modified the third paragraph of the Introduction, adding the following sentence: "Addressing the lack of HBV summary data in the UK would aid researchers and policy makers in addressing further evidence gaps". We also include information concerning EHRs in the UK in the discussion.**

- Introduction. It should be stated clearly in the aims that this is a narrative review (for readers who may confuse this with a systematic review and meta-analysis). **Thank you, we've now explicitly stated our aims in the Introduction section.**

**Competing Interests:** No competing interests were disclosed.

Reviewer Report 03 January 2023

<https://doi.org/10.21956/wellcomeopenres.19882.r53567>

© 2023 Choi J. This is an open access peer review report distributed under the terms of the [Creative Commons Attribution License](#), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

**Jonggi Choi** 

<sup>1</sup> Department of Gastroenterology, Liver Center, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea

<sup>2</sup> Department of Gastroenterology, Liver Center, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea

The authors extensively reviewed the current data regarding the chronic hepatitis B epidemiology in the UK. The authors also acknowledged limitations on current data about chronic hepatitis B due to the limited source. Therefore, it requires a broad spectrum study to cover entire population to help guide public health policy and control transmittable disease.

I have no further comment on this manuscript.

**Is the work clearly and accurately presented and does it cite the current literature?**

Yes

**Is the study design appropriate and is the work technically sound?**

Yes

**Are sufficient details of methods and analysis provided to allow replication by others?**

Yes

**If applicable, is the statistical analysis and its interpretation appropriate?**

Yes

**Are all the source data underlying the results available to ensure full reproducibility?**

Yes

**Are the conclusions drawn adequately supported by the results?**

Yes

**Competing Interests:** No competing interests were disclosed.

**Reviewer Expertise:** Hepatology

**I confirm that I have read this submission and believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard.**

Author Response 24 Feb 2023

**Cori Campbell**

We are grateful to reviewers for their helpful comments.

**Competing Interests:** No competing interests were disclosed.

Reviewer Report 13 December 2022

<https://doi.org/10.21956/wellcomeopenres.19882.r53571>

© 2022 Mak L. This is an open access peer review report distributed under the terms of the [Creative Commons Attribution License](#), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

? **Lung-Yi Mak** 

<sup>1</sup> Department of Medicine, Queen Mary Hospital, The University of Hong Kong, Hong Kong, China

<sup>2</sup> Department of Medicine, Queen Mary Hospital, The University of Hong Kong, Hong Kong, China

This is an extremely important piece of work to estimate the epidemiology of HBsAg+ seropositivity in the UK. The authors summarized data from 6 sources, leading to a crude estimate for HBsAg seropositivity ranging from 0.27-0.73%. The following points should be addressed to further enrich the scientific contents and provide some directions for further research:

1. Ongoing pilot programs of universal HBV testing at Emergency Departments are being conducted in some NHS Trusts, especially after the COVID-19 pandemic. Would there be any chance that updated data from these pilot programs might have been recently reported and can be included in this piece?
2. Regional differences within the country, or even to a smaller scale, within a city, should also be appreciated. For instance, East London is likely having a much higher prevalence of HBsAg+ than the West/ North side of the city. While population-based data is very important, targeting high-risk groups (as the authors also addressed) is equally crucial to inform healthcare strategies such as resource allocation. This is also relevant to UK in view of the low overall prevalence of HBsAg (<2%, according to data presented), and population-based screening may not be as cost-effective as other highly endemic regions. Although the CDC has updated the recommendations since 2022 to screen for HBV infection for at least once in the lifetime for all adults, the actual implementation of such approach will highly depend on the resources available. Therefore, it would be helpful if there is data for HBsAg seroprevalence in the high-risk groups; and in addition to that addressed in this article (sexual health, antenatal, emergency medicine, people born in high-prevalence setting), regions that are traditionally considered to be impoverished areas or known to harbour a relatively high proportion of immigrants, should be the target groups for such opportunistic approaches.
3. Would there be any overlap between the laboratory-identified HBsAg+ cases from UKHSA with other data sources? (i.e., the primary care database QResearch, CPRD primary care database and the antenatal screening programme)
4. Risk of bias and sampling error is well acknowledged – the authors may also include data from the NHS Blood and Transplant study published in Transfusion 2021 which reported a seroprevalence of HBsAg+ being 6.9/ 100,000 donors between 2009-2018.

**Is the work clearly and accurately presented and does it cite the current literature?**

Partly

**Is the study design appropriate and is the work technically sound?**

Yes

**Are sufficient details of methods and analysis provided to allow replication by others?**

Yes

**If applicable, is the statistical analysis and its interpretation appropriate?**

Not applicable

**Are all the source data underlying the results available to ensure full reproducibility?**

Yes

**Are the conclusions drawn adequately supported by the results?**

Partly

**Competing Interests:** No competing interests were disclosed.

**Reviewer Expertise:** chronic hepatitis B infection, clinical liver disease

**I confirm that I have read this submission and believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard, however I have significant reservations, as outlined above.**

---